《Rapid development of a bromochloropyridine regioisomer purity method enabled by strategic LC screening》 was published in Journal of Pharmaceutical and Biomedical Analysis in 2020. These research results belong to Borges-Munoz, Amaris; Li, Li; Tattersall, Peter. Product Details of 53939-30-3 The article mentions the following:
With the intent to provide aligned, impactful, and efficient strategies for liquid chromatog. method development, tier-based stationary/mobile phase screening workflows have been implemented in the Chem. Process Development department at Bristol Myers Squibb. These workflows are utilized as tools that enable more rapid method generation for early to mid-stage clin. development programs. An illustrative example of applying this approach was the method development for 3-bromo-2-chloropyridine and six of its positional isomeric impurities. Several parameters (gradient time, flow rate, column geometry, particle size, temperature, and solvent effects) were evaluated to achieve a baseline resolved separation for this challenging mixture The impact that the screening workflows have regarding timesavings, effort, and resourcing to develop and optimize this LC method will be discussed. In the experiment, the researchers used 5-Bromo-2-chloropyridine(cas: 53939-30-3Product Details of 53939-30-3)
5-Bromo-2-chloropyridine(cas: 53939-30-3) belongs to pyridine. Pyridine’s structure is isoelectronic with that of benzene, but its properties are quite different. Pyridine is completely miscible with water, whereas benzene is only slightly soluble. Like all hydrocarbons, benzene is neutral (in the acid–base sense), but because of its nitrogen atom, pyridine is a weak base.Product Details of 53939-30-3